

ENTERPRISE ANALYSIS AND DESK RESEARCH

NAME :ADITYA TIWARI

E-COMMERCE

FOUNDERS AND PROMOTERS OF SERUM INSTITUTE OF INDIA

- Cyrus S. Poonawalla is an Indian billionaire businessman, and the chairman and managing director of the Cyrus Poonawalla Group, which includes the Serum Institute of India, an Indian biotech company which is the largest vaccine manufacturer in the world and Poonawalla Fincorp a leading NBFC in India. Wikipedia
- Born: 11 May 1941 (age 81 years), Pune
- Organization founded: Serum Institute of India
- Grandchildren: Darius Poonawalla, Cyrus Poonawalla
- Nephew: Yohan Poonawalla
- Awards: Padma Bhushan, Padma Shri
- Children: Adar Poonawalla
- Education: Brihan Maharashtra College of Commerce (1966), The Bishop's School



MISSION AND VISION

- It is the mission of Serum Institute to develop quality vaccines and offer them at inexpensive prices, thus facilitating several countries to improve their Health Index.



MANAGEMENT STRUCTURE

Current board members & directors are

- Suresh Sakharam Jadhav,
- Cyrus Soli Poonawalla,
- Zavareh Soli Poonawalla,
- Adar Cyrus Poonawalla,
- Behroze Zavareh Poonawalla,
- Natasha Adar Poonawalla,
- Rajeev Mhalasakant Dhere,
- Satish Damodar Ravetkar,
- Satish Ramchandra Mundra
- Mrudula Arvind Phadke .

FINANCIAL STRUCTURE

- Here is a summary of financial information of SERUM INSTITUTE OF INDIA PRIVATE LIMITED for the financial year ending on 31 March, 2022. Revenue / turnover of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is Over INR 500 cr.
- Net worth of the company has increased by 50.80 %
- EBITDA of the company has increased by 310.76 %
- Total assets of the company has increased by 40.41 %
- Liabilities of the company has decreased by -11.71 %

CHALLENGES FACED BY SERUM INSTITUTE OF INDIA DURING COVID-19

- India; Covid-19
- Vaccination Strategy
- Vaccine Manufacturing
- Vaccine Exports
- Vaccine Diplomacy

SALES FORECAST OF SERUM INSTITUTE OF INDIA DURING COVID-19

- Serum Institute of India (SII) recorded a revenue of Rs 7201 crore during FY 20-21, exhibiting a growth of 44 per cent in comparison to the revenue generation of Rs 5014 crore in FY 19-20.
- At the beginning of FY 20-21, SII announced its partnership with the University of Oxford in the UK for the trial of its COVID-19 vaccine candidate Covishield, in coordination with the Indian Council of Medical Research (ICMR) and AstraZeneca. In the later months, the company entered into a landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low and middle-income countries (LMICs).

SALES OF SERUM INSTITUTE OF INDIA DURING COVID AND POST COVID

- The company's income and net profit have followed growth trajectory for many years. The vaccine-maker reported net profit of Rs 1,741.33 crore in FY14; Rs 1,963.89 crore in FY15; Rs 2,179 crore in FY16; Rs 2,057 crore in FY17; Rs 1,912 crore in FY18; Rs 2,252 crore in FY19 and Rs 2,251 crore in FY20. Net income increased from Rs 3,636.2 crore in FY14 to Rs 5,871 crore in FY19 to Rs 5,926 crore in FY20.

